Compare Novartis AG (NVS) vs Sempra Energy (SRE) Price & Performance

Novartis AGTrade

Sempra EnergyTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Sempra Energy — how do they compare? Novartis AG trades at $138.16 (market cap $262.64B), while Sempra Energy trades at $84.9 (market cap $55.89B). The key difference: Novartis AG is far larger — about 4.7× Sempra Energy's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.

	NVS	SRE
Market Cap	$262.64B	$55.89B
Sector	Health	Utilities
52-Week High	$168.62	$99.75
52-Week Low	$121.80	$81.70
Enterprise Value	$303.97B	$92.52B
Dividend Yield	3.44%	3.08%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Sempra Energy

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis shares plunge 12.5% after two Phase 3 drug trials fail primary goalsPRNewsWire · 17 hours agoBearish Amgen shares drop 10% after Novartis fails cholesterol drug trial, despite Amgen's own cancer trial success.24/7 Wall Street · 1 day agoBearish Novartis shares drop 10% after del-desiran fails Phase 3 trial for myotonic dystrophyProactive Investors · 1 day agoBearish View details →

SRE

Sempra rings NYSE bell, announces $65B capital plan to expand U.S. utility infrastructure.PRNewsWire · 1 day agoBullish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About Sempra Energy

Sempra is an energy infrastructure company with regulated utility and energy network businesses. Its operations include electric and gas utilities as well as energy infrastructure in North America.